13G
| | |
CUSIP No. 56600D 107 | | Page 10 of 19 Pages |
Maravai LifeSciences Holdings, Inc. (the “Issuer”).
Item 1(b) | Address of Issuer’s Principal Executive Offices: |
10770 Wateridge Circle, Suite 200, San Diego, California 92121
Item 2(a) | Name of Person Filing: |
This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1(k) promulgated by the Commission pursuant to Section 13 of the Act: (i) Maravai Life Sciences Holdings 2, LLC (“MLSH 2”), (ii) Maravai Life Sciences Holdings, LLC (“MLSH 1” and collectively with MLSH 2, the “MLSH Entities”) (iii) GTCR Fund XI/C LP, which controls the board of managers of MLSH 2 (iii) GTCR Fund XI/B LP, (iv) GTCR Co-Invest XI LP, which together with GTCR Fund XI/B LP, controls the board of managers of MLSH 1, (v) GTCR Partners XI/A&C LP, which is the general partner of GTCR Fund XI/C LP, (vi) GTCR Partners XI/B LP, which is the general partner of GTCR Fund XI/B LP, and (vii) GTCR Investment XI LLC, which is the general partner of each of GTCR Co-Invest XI LP, GTCR Partners XI/A&C LP and GTCR Partners XI/B LP. Collectively, the MLSH Entities, GTCR Fund XI/C LP, GTCR Fund XI/B LP, GTCR Co-Invest XI LP, GTCR Partners XI/A&C LP, GTCR Partners XI/B LP and GTCR Investment XI LLC are the “Reporting Persons.”
The Reporting Persons have entered into a Joint Filing Agreement, dated February 11, 2021, a copy of which is attached as Exhibit A to this Statement, pursuant to which the Reporting Persons agreed to file this Schedule 13G and any amendments thereto jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.
Item 2(b) | Address of Principal Business Office or, if none, Residence: |
The principal business address of each of the GTCR Entities is 300 North LaSalle Street, Suite 5600, Chicago, IL, 60654
See response to Item 4 of each of the cover pages.
Item 2(d) | Title of Class of Securities: |
Class A common stock, par value $0.01 per share.
56600D 107